Curacle Co EV/FCF

Mitä Curacle Co tekee? Curacle Co Ltd is a biotechnology company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on research and experimental development in medical sciences and pharmacy, with a specific emphasis on developing treatments for intractable vascular diseases. As of the latest available information, Curacle employs 35 full-time staff members. The company completed its initial public offering (IPO) on July 22, 2021. Curacle is developing synthetic drugs including CU06-RE, CU01, and a natural drug referred to as CU03, which are targeted at conditions such as diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company utilizes a platform technology known as SOLVADYS, designed for the development of vascular endothelial dysfunction blockers. Curacle's website is http://www.curacle.com, providing further details about its research and development activities. The company's operations are centered around innovative drug development aimed at addressing significant unmet medical needs in vascular disease treatment. No additional details about founding year, specific executives, or financial figures beyond the IPO date are provided in the available information. Curacle Co on yksi Eurpooliin suosituimmista yhtiöistä.